Everyday Freedom™for your employees

A breakthrough treatment for anxiety attacks and PTSD symptoms

Freespira is the only FDA-cleared treatment proven to reduce or eliminate panic attacks and post-traumatic stress disorder (PTSD) symptoms. Unlike medication or talk therapy, in 28 days Freespira addresses underlying breathing irregularities common in individuals suffering from these debilitating conditions.

Living with anxiety attacks or traumatic stress symptoms can be scary.

Typical symptoms may include:

CHEST PAINS

SHORTNESS OF BREATH

UNCOMFORTABLE FLASHBACKS

Freespira is helping to break down access barriers as an at-home treatment option for panic disorder and PTSD that does not require a doctor or therapist visit.

symptoms_right
This has been life-changing for me, and it is a tool I will use for life.
— Freespira Patient
Something has changed inside of me, and I feel so much more control over my panic and strong emotions.
— Freespira Patient

Freespira is helping to break down access barriers as an at-home treatment option for panic disorder and PTSD that does not require a doctor or therapist visit.

Schedule a product demo

Practical, proven treatment for anxiety attacks

Panic attacks and PTSD impact plan spend. These conditions lead to significantly higher average additional claims spend per patient:

PANIC DISORDER
$5,3251
PTSD
$13,9812
13.6%
Combined, comorbid prevalence of panic disorder and ptsd adults and teens3

Panic attacks accompany a range of other health conditions. The 28.3% lifetime prevalence of panic attacks means many people experience a panic attack without meeting the full diagnostic criteria for panic disorder.4

98%

Panic disorder patients have at least one behavioral health comorbidity; among the most common, major depressive disorder, anxiety disorder, and alcohol use disorders5

avrage_icon
Freespira is easy to use, with high adherence averaging 75%.10
home_icon
Freespira is an accessible at-home treatment that doesn’t require a doctor’s visit.
fda_icon
Freespira is the only FDA-cleared, medication-free digital therapeutic proven to reduce or eliminate panic attacks and PTSD symptoms.
Freespira is proven to lower total medical plan costs by 35%.11
I now notice when my chest tightens from anxiety and then I focus on my breath and the symptoms go away. I feel like I have learned to take control of my anxiety and I will use this awareness for the rest of my life.

— Freespira Patient

Freespira Reduced Total Cost of Care by 35%6

In peer-reviewed studies:

Patients experienced symptom reduction:

85%
Patients saw significant reduction in symptoms of panic disorder at 12-months6, 7
82%
Panic disorder patients with significantly fewer symptoms one year post-treatment6
73%
Patients still panic attack free one year post-treatment8
89%
PTSD patients had clinically significant reductions in symptoms 6 months later7
50%
PTSD patients were in remission 6 months later7

Plan saw reduction in medical costs6:

65%
Reduction in emergency department costs
68%
Reduction in pharmacy costs
35%
Reduction in total medical costs

Download our Comcast/Crossover Health study overview.

Download Now

Get started with accessible mental health support

Freespira does not require a doctor or therapist appointment, making it an accessible option not dependent on provider availability.

Typical implementation in 6+ weeks is guided by an onboarding manager and includes targeted multi-channel communications to expand employee awareness.

accessible_img

Freespira is a medication-free, twice daily treatment that normalizes breathing behavior which eliminates or reduces panic and PTSD symptoms. Each Freespira patient receives a sensor and tablet and is assigned a dedicated coach to virtually guide them through treatment sessions. After 28 days, more than 80% of patients saw a significant reduction in symptoms of panic disorder and PTSD.6, 7

Help employees stop anxiety attacks.

LEARN MORE

*Freespira is indicated (FDA-cleared) as an adjunctive treatment of symptoms associated with panic disorder, panic attacks and/or PTSD in patients 18 and older. In younger patients, Freespira has been evaluated and is being made available as permitted by FDA’s COVID-19 Enforcement Discretion Guidance.

1 See Konnopka, et al., https://pubmed.ncbi.nlm.nih.gov/31646432/
2 See National Academies, https://pubmed.ncbi.nlm.nih.gov/25077185/
3 See National Institutes of Health, https://www.nimh.nih.gov/health/statistics/panic-disorder
4 See Kessler, et al., https://pubmed.ncbi.nlm.nih.gov/16585471/
5 See Virpi, et al., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3520420/
6 See Kaplan, et al., https://doi.org/10.1007/s10484-020-09465-0
7 See Ostacher, et al., https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8553693/
8 See Tolin, et al., https://pubmed.ncbi.nlm.nih.gov/28194546/